Abstract: An ultrasound imaging system may acquire an image of a liver. The liver may be segmented from the image. Parameters, such as image homogeneity map, intensity probability chart, and/or speckle size diagram, may be extracted from the liver portion of the image. The parameters may be used to determine whether fatty liver deposits are diffuse or inhomogeneous. In some examples, inhomogeneous regions may be excluded from the calculation of liver fat quantification measurements. In some examples, the inhomogeneous regions may be displayed so that a user may select a region of interest that excludes the inhomogeneous regions to calculate the liver fat quantification measurements.

Abstract: Disclosed is an execution information sharing system that duplicates execution information to a provider target (and other targets) as it is being loaded to a consumer target. A first log information object and a second log information object are generated. The first and second log information objects comprise information indicating a consumer target and information indicating a provider target respectively where execution information generated by an application shared with a consumer account of a data exchange is written. A first event unloader and a second event unloader are generated based on the first and second log information objects respectively, wherein the first and second event unloaders are both linked to the application using a mapping. In response to receiving execution information from the application, the execution information is forwarded to the consumer target and the provider target using the first event unloader and the second event unloader respectively.

Abstract: Disclosed is an execution information sharing system that writes execution information to a provider target (and other targets) in a secure manner. Execution information generated by an application may be written to a consumer stage, wherein the application is shared by a provider account of a data exchange with a consumer account that executes the application. A consumer exchange service (ES) of the data exchange may send a request to a copy service of the data exchange to copy the execution information from the consumer stage to the provider stage, wherein the consumer ES is a part of the data exchange and is protected from actions of the consumer account. A copy operation may be executed to copy the execution information from the consumer stage to the provider stage using the copy service of the data exchange. The execution information is ingested from the provider stage to a provider table.

Abstract: Provided herein are systems and methods for configuring trace events. A system includes at least one hardware processor coupled to a memory and configured to instantiate a user code runtime to execute user-defined function (UDF) code. The user code runtime is instantiated within a sandbox process of an execution node. An application programming interface (API) call is detected during execution of the UDF code. The API call includes one or more configurations of a trace event. Telemetry information is collected based on the one or more configurations. The telemetry information is associated with the trace event using a telemetry API. The telemetry API corresponds to the API call. The telemetry information is formatted using the telemetry API, to generate structured telemetry information. The at least one hardware processor causes ingestion of the structured telemetry information into an event table.

Abstract: Disclosed is an execution information sharing system that duplicates execution information to a provider target (and other targets) as it is being loaded to a consumer target. A consumer account of a data sharing platform executes an application shared with it by a provider account of the platform. Consumer and provider configurations indicating consumer and provider targets respectively are generated. The consumer configuration and provider configurations are provided to an event context to generate a first and second event unloaders respectively, wherein the event context maintains a mapping linking both the first event unloader and the second event unloader to the application. In response to receiving execution information from the application, the first event unloader and the second event unloader are retrieved. The execution information is then written to the consumer target and the provider target using the first event unloader and the second event unloader respectively.

Abstract: A method of treating psoriatic arthritis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant improvement in clinical endpoints, such as ACR20/50/70, IGA, HAQ-DI, CRP, SF-36 PCS/MCS, MDA, VLDA, enthesitis, dactylitis, and LEI/dactylitis, as measured 16 and 24 weeks after initial treatment.

Abstract: A method of treating psoriatic arthritis in a patient having showed an inadequate response to treatment with an anti-TNF therapy by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant ACR20/50/70, IGA, HAQ-DI, CRP, SF-36 PCS/MCS, MDA, VLDA, enthesitis, dactylitis, and LEI/dactylitis improvement as measured 16, 24 and 48 weeks after initial treatment.

Abstract: A method of treating psoriatic arthritis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant ACR20/50/70, IGA, HAQ-DI, CRP, SF-36 PCS/MCS, MDA, VLDA, enthesitis, dactylitis, and LEI/dactylitis improvement as measured 16 and 24 weeks after initial treatment.

Abstract: A method of treating psoriatic arthritis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant ACR20/50/70, PASI70/90/100, MDA, HAQ-DI, SF-36 PCS, MCS, LEI/dactylitis, PASDAS, GRACE, mCPDAI, DAPSA or RAPID3 improvement as measured 16, 24, 32, 40 and 48 weeks after initial treatment.

Abstract: A method of treating psoriatic arthritis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant improvement in clinical endpoints, such as ACR20/50/70, IGA, HAQ-DI, CRP, SF-36 PCS/MCS, MDA, VLDA, enthesitis, dactylitis, and LEI/dactylitis, as measured 16 and 24 weeks after initial treatment.

Abstract: This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the SEM A4D gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the SEMA4D gene.

Abstract: This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the ADAM10 gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the ADAM10 gene.

Abstract: This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the CACNA1E gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the CACNA1E gene.

Abstract: This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the SEM A4D gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the SEMA4D gene.